ŌURA and LillyDirect, Eli Lilly’s digital health platform, have announced a collaboration to support people using GLP-1 weight-loss and diabetes therapies by combining access to wearable technology with behavioral health tools. Under the partnership, LillyDirect customers will receive a complimentary Oura Ring sizing kit, making it easier to purchase the wearable. The companies emphasized that the collaboration does not involve sharing patient data, but instead aims to create a broader ecosystem of care that complements prescribed GLP-1 medications.
The partnership builds on Oura’s recently launched GLP-1 Insights feature, which integrates continuous biometric tracking with therapy-specific insights. Using data from the Oura Ring, patients can monitor sleep, activity, readiness, stress, and other physiological metrics alongside their GLP-1 treatment, helping them understand how daily habits influence treatment outcomes beyond weight loss alone. Oura says tens of thousands of its members already log GLP-1 use within the app, with adoption expected to grow as use of these medications expands worldwide.